AbbVie | ABBV - Operating Profit

Stock Price
225.66
Daily Change
0.02 0.01%
Monthly
2.49%
Yearly
18.80%
Q1 Forecast
216.14

AbbVie reported $5.72B in Operating Profit for its fiscal quarter ending in June of 2025.





Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Abbott USD 2.25B 73M Dec/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Eisai JPY 13.67B 7.07B Sep/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
GlaxoSmithKline GBP 2.79B 764M Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Medtronic USD 1.7B 100M Sep/2025
Merck USD 6.55B 189M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD 4.5B 363M Sep/2025
Pacira USD 13.15M 2.92M Sep/2025
Perrigo USD 93.4M 37.8M Sep/2025
Pfizer USD 652M 3.67B Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
UCB EUR 1B 678M Dec/2024
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025
Zoetis USD 936M 63M Sep/2025